Extended Data Fig. 6: Ability of BYL719 to inhibit PIK3CA activation in different tissues.
From: Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Immunofluorescence staining of P-AKT (Ser473) and P-S6RP in the liver (a), heart (b), spleen (c) and muscles (d) of PIK3CAWT and PIK3CACAGG-CreER mice treated with or without BYL719 (n = 8 mice per group). Scale bars, 10 μm.
